Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand.
Jintanat Ananworanich, Leigh Anne Eller, Suteeraporn Pinyakorn...
https://pubmed.ncbi.nlm.nih.gov/28691436Actively Recruiting
Phase 3
Age: 18Years +
All Genders
ID00796263
Antiretroviral Therapy for Acute and Chronic HIV Infection
Led by SEARCH Research Foundation · Updated on 2025-06-04
900
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
S
SEARCH Research Foundation
Lead Sponsor
V
ViiV Healthcare
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating antiretroviral therapy (ART) for people with acute and chronic HIV infection. This study compares outcomes in different body tissues, including genital secretions, central nervous system, gut, and lymph nodes, among individuals starting treatment during acute versus chronic HIV infection. The study includes participants from two related HIV studies in Thai populations, focusing on immune and virologic responses at various infection stages and ART regimens. Participants receive a highly active antiretroviral therapy (HAART) regimen consisting of one or two nucleoside/nucleotide reverse-transcriptase inhibitors plus dolutegravir (DTG) 50 mg taken orally once daily. The treatment aims to evaluate HIV control and immune function over time. The study follows participants long-term to assess clinical, immunologic, and virologic outcomes, comparing those who start treatment early with those treated during chronic infection. During the study, participants undergo regular monitoring of HIV-related clinical events, immune cell counts, viral load, and drug resistance. Assessments also include functional brain imaging, neuropsychological testing, and analysis of immune activation markers in blood and tissue samples. Researchers track adherence to ART and adverse events related to treatment. The total follow-up period extends over 10 years, allowing comprehensive evaluation of treatment effects and disease progression.
CONDITIONS
Brief Title
Antiretroviral Therapy for Acute and Chronic HIV Infection
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Enrolled in the SEARCH 010 or SEARCH 013 protocols with documented acute or chronic HIV-1 infection
- Able to understand the study and provide informed consent (including use of thumb print if unable to read)
- Available for follow-up for the planned study duration
You will not qualify if you...
- History of medical or psychiatric disorder that interferes with study adherence or ability to consent, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 10 years
Participants receive antiretroviral therapy consisting of 1 or 2 nucleoside/nucleotide analog reverse-transcriptase inhibitor medications plus dolutegravir 50 mg orally once daily.
Regular follow-up visits to monitor treatment adherence, HIV-related clinical events, and immune and virologic parameters
Trial Site Locations
Total: 1 location
1
Institute of HIV Research and Innovation
Bangkok, Thailand, 10330
Actively Recruiting
Loading map...
Research Team
N
Nitiya Chomchey, RN, PhD
T
Tassanee Luekasemsuk, MSc
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology.
Mark S de Souza, Suteeraporn Pinyakorn, Siriwat Akapirat...
https://pubmed.ncbi.nlm.nih.gov/27317797